Cardiac Surgery

Bergamo, Italy

Cardiac Surgery

Bergamo, Italy
SEARCH FILTERS
Time filter
Source Type

(PRLEAP.COM)– According to a new series of reports on the U.S. market for diagnostic ophthalmic devices by iData Research ( www.idataresearch.com ), manufacturers are introducing new technologies into fundus camera systems, including angiography and fluorescent dye tracking. As a result, total fundus camera unit sales are moderately growing. Table mounted sales for both imaging modalities are being driven by the replacement of older technology. The natural growth of the market associated with the increase in the elderly populations which is directly correlated with the incidence of ocular disease.This market includes mydriatic and non-mydriatic fundus cameras. Each of the segments are further divided into table mounted and handheld devices. The persistent growth of the market is driven by the prevalence of age-related ocular conditions, such as glaucoma and macular degeneration. However, the average selling price for the total fundus camera market will depreciate over the next several years. This decrease can partially be attributed to the influx of inexpensive handheld devices and the competitive nature of the market that is being seen across all fundus camera segments. As a result, the significantly less expensive handheld mydriatic market is strongly outpacing the unit growth of the established table mounted market. Furthermore, the table mounted market is losing ground to combination devices which incorporate fundus cameras into other ophthalmic equipment."Traditionally the non-mydriatic fundus camera has been the choice of optometrists for several reasons; it is less expensive, the additional capabilities were not used as much by optometrists, and the need for chemical pupil dilation was an inconvenience for patients post procedure," explains Jeffrey Wong, Strategic Analyst Manager at iData Research. "This is beginning to change as the increased range of capabilities offered by mydriatic cameras can also be a competitive advantage for an optometrist seeking patients."Topcon is the leading competitor in the U.S. fundus camera market. The company manufactures table mounted fundus cameras for both the mydriatic and non-mydriatic market. As part of the table mounted non-mydriatic fundus cameras Topcon manufactures the TRC-NW8®, TRC-NW8F® and the TRC-NW400®. In the mydriatic market Topcon manufactures the TRC-50DX® Series.Carl Zeiss Meditec is the second leading competitor in the U.S. fundus camera market. The company manufactures five fundus cameras, and participates in all segments of this market. Their latest fundus camera, the VISUCAM® 224 has a 24-megapixel sensor for high resolution images. Additional competitors in the U.S. fundus camera market include Canon and Kowa among others.More on the fundus camera market in the U.S can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Diagnostic Ophthalmic Devices . The suite covers reports on the following markets: Ophthalmic coherence tomography, fundus cameras, data management systems, slit lamps, perimeters, tonometers, autorefractors/keratometers, binocular indirect ophthalmoscopes, ophthalmic ultrasound devices, wavefront abberometers, corneal topographers and optical biometers.The iData report series on ophthalmic devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about ophthalmic device market data, register online or email us at info@idataresearch.net for a U.S. Market Report Suite for Diagnostic Ophthalmic Devices brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Ophthalmics, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Vascular Access, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Endoscopy, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Dental Operatory Equipment and more.We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.


DUBLIN, May 24, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Fixed And Mobile C-arms Market Analysis By Product (Fixed & Mobile Size: Full-size/Mini C-arm), By Application (Orthopedics, Neurosurgery, Cardiac Surgery, Vascular Surgery, Pain...


DUBLIN, May 26, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Cardiac Surgery Instruments Market by Product, Application & End User - Global Forecast to 2022" report to their offering. The cardiac surgery instruments market is expected to reach...


Leonard Octavius Barrett, MD, FACS, DDG, FABI, Thoracic Surgeon at Nassau University Medical Center, has been named a 2017 Top Doctor in East Meadow, New York. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. Dr. Leonard Octavius Barrett is a very experienced surgeon, having been in practice for over three decades. His career in medicine began in 1983, when he graduated from the State University of New York Downstate Medical College. After an internship and residency at Stony Brook University Hospital, Dr. Barrett completed a further residency at the Newark Beth Israel Medical Center, before undertaking a fellowship at Winthrop-University Hospital in Mineola, New York. Dr. Barrett is board certified in Surgery, Surgical Critical Care, and Thoracic and Cardiac Surgery, and he has become known as one of New York’s leading thoracic surgeons. He treats a wide range of conditions for patients across the age spectrum, including heart murmurs and arrhythmias, carotid artery disease, vascular disease, and lung cancer. He currently serves as Chief of Thoracic Surgery and Director of Surgical Critical Care at the Nassau University Medical Center. Dr. Barrett is committed to keeping up to date with the latest advances in the field of thoracic surgery, and he does through his membership of professional organizations including the Society of Critical Medicine and the American Society of Thoracic Surgery. He has earned the coveted title of Fellow of the American College of Surgeons, and his dedication and commitment makes Dr. Leonard Octavius Barrett a very deserving winner of a 2017 Top Doctor Award. Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.


Despite increasing unit sales, increased competitiveness within the total patient monitoring market has had a negative impact on market growth. The entry of low cost foreign competition has been especially disruptive. However, the long-term prospects remain positive as demand for quality patient monitoring solutions will enable unit sales growth to outpace pricing pressure. Philips Healthcare is the leading competitor in the Australian patient monitoring market. The company competes in the multi-parameter vital sign monitoring market, wireless telemetry, pulse oximetry and fetal/neonatal monitoring markets. Their IntelliVue™ and SureSigns™ product lines range from low to high-acuity and have flexible product designs ranging from extremely compact to portable bedside units. GE Healthcare is the second leading competitor in the Australian patient monitoring market. GE offers an extensive product line that not only includes a range of low- to high-acuity monitoring devices, but also telemetry devices and networking solutions. Their product lines include the CARESCAPE™ B series and new B40™ patient monitors which can feed into the CARESCAPE™ central stations and mobile viewers to access patient information. Additional competitors in the Australia patient monitoring market include Dräger Medical, Medtronic, Mindray, Nihon Kohden, Natus Medical, Compumedics, Welch Allyn, Spacelabs Healthcare, Nonin and Smiths Medical among others. More on the patient monitoring device market in Australia can be found in a series of reports published by iData Research entitled the Australia Market Report Suite for Patient Monitoring Equipment. The suite covers reports on the following markets: multi-parameter vital signs monitoring, wireless ambulatory telemetry monitoring, telehealth, electromyogram monitoring, electroencephalogram monitoring, fetal and neonatal monitoring, pulse oximetry and blood pressure monitoring devices. The iData report series on patient monitoring devices covers the U.S., China, Australia, India, Japan, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about patient monitoring device market data, register online or email us at info@idataresearch.net for an Australia Market Report Suite for Patient Monitoring Equipment brochure and synopsis. iData Research (www.idataresearch.com) is an international market consulting research firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Laparoscopy, Urology, Gynecology, Endoscopy, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/philips-and-ge-healthcare-lead-the-australia-patient-monitoring-equipment-market-due-to-the-adoption-of-less-invasive-more-accessible-patient-centric-device-configurations-300464048.html


The ASP decline is reinforced by competition among discount and value companies. However, the moderate growth rate of the U.S. dental implant industry has spurred the development and acceptance of technologies that facilitate dental implant placement and restoration. In turn, these technological advancements will further drive dental implant replacement rates. Additionally, technological advancements incorporated into dental software suites are set to drive sales, especially software that falls under premium brands. However, downward price pressure and the market entry of low-cost competitors will continue to offset gains in unit sales, resulting in moderate market values. The market has been restructuring, with discounted and value brands gaining popularity in the market. Generic and imitation abutments are growing more acceptable. Instrument kits are increasingly being given away. Treatment planning software is now bundled to help retain loyal customers. Discounted surgical guides are growing more prevalent. These market limiters have largely impacted market value and revenue potential in the overall U.S. market. The dental implant fixtures and final abutments market in the U.S. is largely controlled by three main companies: Nobel Biocare, Straumann and Dentsply Sirona. In addition to their current dominance in the market, they are also very active with ongoing acquisitions to further secure their leading positions. The leading competitors have also been able to maintain their ranking through a history of brand loyalty. The dental market is dominated by specialists such as periodontists and oral surgeons, who generally prefer premium brands. As a consequence, the premium companies are expected to maintain their dominance in upcoming years. As discount and value brands continue to emerge on the market, premium leaders are expected to continually lose market share. However, the market leaders have engaged in price cutting and bundling of large-scale purchases to remain competitive. Additional competitors in the U.S. dental implant fixtures market include Zimmer Biomet, BioHorizons, Implant Direct and MIS Implants among others. More on the dental implant market in the U.S. can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Dental Implant Fixtures and Final Abutments. The suite covers reports on the following markets: dental implant fixtures, final abutments, dental implant instrument kits, treatment planning software and surgical guides. The iData report series on dental implants covers the U.S., Argentina, Brazil, Mexico, China, Australia, Japan, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about dental implant market data, register online or email us at info@idataresearch.net for a U.S. Market Report Suite for Dental Implant Fixtures and Final Abutments brochure and synopsis. iData Research (www.idataresearch.com) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Laparoscopy, Urology, Gynecology, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nobel-biocare-straumann-dentsply-sirona-lead-us-dental-implant-fixtures-market-despite-pricing-pressure-from-low-cost-competitors-300464649.html


News Article | May 23, 2017
Site: www.marketwired.com

VANCOUVER, BC--(Marketwired - May 23, 2017) - Lexington Biosciences, Inc. ( : LNB) (LNB.CN) ( : LNB) (the "Company" or "Lexington"), a development-stage medical device company operating within the healthcare industry, is pleased to introduce and welcome Mr. Eric Willis as Company President, and Mr. Doug Janzen as Board Chairman. Mr. Willis is a twenty plus year veteran of the healthcare technology industry with a passion for working closely with clinicians to bring products from concept to market. Previously he was the President and CEO of InSite Medical Technologies, a developer of products for anesthesiologists to reduce critical complications and procedure times for surgical and labor and delivery patients. He was also the President of ParaPatch, the General Manager of Atia Medical, and previously served as Director of New Therapies for Guidant Cardiac Surgery, as well as having held a variety of core product development roles for Foxhollow, Heartport; and DVI/Guidant. He has been responsible for developing a multitude of products in the fields of interventional cardiology, cardiac surgery, anesthesiology, ophthalmology, and women's health, and is listed as an inventor on many issued & pending patents. His educational background includes degrees in Mechanical Engineering from Stanford University and the University of California at Santa Barbara. In his personal life, he is a competitive sailor, mountain biker, and obstacle course racer. Mr. Janzen brings over 20 years of experience in life sciences with leadership experience in corporate finance, business development, and operational management of life sciences companies. He is currently Co-Founder and Managing Director of Northview Ventures. He serves as Chairman and CEO of Aequus Pharmaceuticals (founded within Northview). Previously he was President and CEO of Cardiome Pharma as well as several other key executive roles during his eight years with the company. His service at Cardiome included raising over $300 million, completion of over $1 billion in licensing, and a partnership with Merck to bring Cardiome's lead product through clinical approval and to market in Europe. Mr. Janzen currently serves on the Boards of Aequus Pharmaceuticals (Chairman), Alabaster Technologies (Chairman), Abcellera (Chairman), Perimeter Medical Imaging (Chairman), Renaissance Biosciences and Synaptive Technologies. Prior to Cardiome he was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences and has completed over $1B in equity financing for Canadian biotech companies. Mr. Janzen is Past Chair of LifeSciences BC and currently serves on their Board, has served as a Director with Biotech Canada and is a past winner of Business in Vancouver's "Top 40 under 40 Award." Company President Eric Willis notes, "We are delighted to be bringing the HeartSentry to the marketplace as a new way of quickly and easily measuring fundamental markers of a patient's cardiovascular health in order to more effectively predict future cardiovascular events. The development of HeartSentry as a simple, easy to use, yet clinically relevant tool to monitor changes in cardiovascular function represents a significant opportunity to improve patient outcomes and to save millions of dollars in preventable health care costs to health systems worldwide. We are rapidly advancing the development of the device towards clinical trials and are assembling a world-class team with the proven expertise for building shareholder value while bringing our product successfully to market within a very rapid timeline. I invite interested readers to visit our website and view our video which clearly outlines our business proposition and opportunity ahead." About Lexington Biosciences, Inc. ( : LNB) Lexington Biosciences is a medical device company that is developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium -- the vital innermost lining of a person's cardiovascular system. Traditionally, this has only been measured using ultrasound and other complex, difficult to use technologies. The HeartSentry technology core research was created at the University of California Berkeley over a fifteen-year period involving many studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. The company is in the final stages of releasing the developed product for clinical studies. The aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit www.lexingtonbiosciences.com and watch our video. CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to the completion of the listing of the Company's shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


The cardiac surgery instruments market is expected to reach USD 1.63 Billion by 2022 from USD 1.16 Billion in 2017, at a CAGR of 7.1%. The market is mainly driven by factors such as high incidence of cardiac diseases, growing prevalence of cardiac conditions and the subsequent increase in the number of surgical procedures, rising geriatric population, and growing investments, funds, and grants by government bodies worldwide. The market in this report is segmented on the basis of products, applications, end users, and regions. Based on product, the market is segmented into forceps, scissors, needle holders, clamps, and other cardiac surgery instruments. The forceps segment dominated the market in 2017, and it is also projected to experience the highest growth during the forecast period. The high growth in this segment is attributed to the increase in the number of cardiac surgeries and the repeated use of forceps in most cardiac procedures. Based on application, the market is further divided into coronary artery bypass graft (CABG), heart valve surgery, pediatric cardiac surgery, and other applications. CABG forms the largest and fastest-growing application segment of the global market. This is mainly attributed to the high incidence of cardiac diseases and the resulting increase in the number of surgical procedures. Heart valve surgery forms the second largest segment. Based on the end user, the market is segmented into hospitals and cardiac centers, and ambulatory surgery centers. The hospitals and cardiac centers segment is expected to dominate the market for cardiac surgery instruments. Growth in this end-user segment can be attributed to the increasing incidence of cardiac and heart valve diseases and the subsequent increase in the number of cardiac surgery procedures. The global market is dominated by North America, followed by Europe. The market in Asia is expected to grow at the highest CAGR during the forecast period. Factors such as increasing awareness programs, high incidence of cardiac diseases, rising number of hospitals, increased cardiac research funding, and improvements in the healthcare sector of Asian countries contribute to the growth of the market in that region. 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Cardiac Surgery Instruments Market, By Product 7 Cardiac Surgery Instruments Market, By Application 8 Cardiac Surgery Instruments Market, By End User 9 Cardiac Surgery Instruments Market, By Region 10 Competitive Landscape 11 Company Profiles For more information about this report visit http://www.researchandmarkets.com/research/cpbrnh/cardiac_surgery To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cardiac-surgery-instruments-market-to-reach-16-billion-by-2022---driven-by-factors-such-as-high-incidence-of-cardiac-diseases-and-increase-in-number-of-surgical-procedures---research-and-markets-300464428.html


LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Bank of America Merrill Lynch (BAML) 2017 Health Care Conference in Las Vegas and at the Jefferies (Jefferies) 2017 Global Healthcare Conference in New York City. The discussion at the BAML conference is scheduled to begin at 9:20 a.m. Pacific Time on Tuesday, May 16, and the discussion at the Jefferies conference is scheduled to begin at 3:00 p.m. Eastern Daylight Time on Thursday, June 8. Both discussions will be available to all interested parties through a live audiocast accessible via the investor relations section of LivaNova’s website at http://investor.livanova.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. A replay of the webcast will be available on the LivaNova website approximately 24 hours after the live presentation for 90 days after the event. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively. For more information, please visit www.livanova.com.


(PRLEAP.COM)– iData Research ( www.idataresearch.com ) recently conducted a face-to-face survey for catheterization lab, structural heart and coronary stents during the 2016 Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, DC. Participants included cardiac surgeons, interventional cardiologists, interventional radiologists and general practitioners. Results have shown that clinical outcomes are the main deciding factor for respondents when choosing which brand of coronary stents to use. Respondents gave reasons for choosing a particular device, including price, availability of devices and existing relationships."This latest report is a global survey regarding demographic trends, concerns, experiences and preferences among cardiologists," explains Dr. Kamran Zamanian, CEO of iData. "Our iData team found answers to the questions posed by major cardiovascular device manufacturers regarding what they wanted to learn from the attendees of TCT 2016."Respondents came from a total of 57 countries. Each country has been subsequently categorized into six distinctive geographical regions: North America, Latin America, Europe, the Middle East, Africa and Asia. Within these regions, the United States, Brazil and Argentina represented the top three countries with the most respondents.The Global Survey on Catheterization Labs, Structural Heart and Coronary Stents by iData Research includes responses for the following questions*:*Results for each question are sorted globally and by regioniData's Global Physician Surveys are conducted by highly trained moderators with years of experience in applying iData's rigorous methodology to ensure balanced responses and to elicit keen insight from physicians, surgeons, specialists and other medical professionals. iData's Global Physician Surveys are used to garner brand awareness, product preferences, message feedback and positioning. iData's Physician Surveys allow the inclusion of a diverse range of medical professionals in broader geographical areas. They also eliminate group bias and allow for interactive one-on-one feedback as well as flexibility to expose the respondent to interactive or static media.iData Research ( www.idataresearch.com ) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.

Loading Cardiac Surgery collaborators
Loading Cardiac Surgery collaborators